Waldenström Macroglobulinemia: Expert Insights on Current and Emerging Treatment Options

Join us for an Independent Satellite Symposium preceding the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting.

Wednesday, September 11, 2019
Hilton Americas
Level 4, Grand Ballroom G-L
1600 Lamar Street
Houston, Texas 77010

6:15 AM – 6:45 AM  ISS Registration and Breakfast
6:45 AM – 7:45 AM  Scientific Program
There is no fee for attending this symposium, however seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.
Program Overview
Waldenström macroglobulinemia (WM) is a rare indolent B-cell lymphoplasmacytic lymphoma that is seen predominantly in older patients. Effective management of WM remains a significant clinical challenge, as there is no single standard-of-care, new treatments are emerging rapidly, and data from head-to-head comparisons of treatment combinations is limited. Additionally, two recently identified mutations, MYD88 and CXCR4, have been shown to have implications on WM prognosis and treatment.
Using a combination of evidence-based presentations and patient case studies, this symposium has been developed to provide essential information about current and emerging treatments for symptomatic WM, including real-world treatment data, and the implications of the MYD88/CXCR4 mutation profile for treatment choice and outcomes.

Join the discussion on twitter: #RMELiveWM

Meletios A. Dimopoulos, MDProgram Chair
Professor and Chair
Department of Clinical Therapeutics
University of Athens School of Medicine

Athens, Greece
Joshua Richter, MD
Assistant Professor of Medicine
Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai
New York, New York


6:15 AM ISS Registration and Breakfast
6:45 AM
Opening remarks and Introduction
Meletios A. Dimopoulos, MD
6:50 AM
Overview of Waldenström Macroglobulinemia
Meletios A. Dimopoulos, MD
7:10 AM
Treatment Options
Joshua Richter, MD
7:30 AM
Concluding Remarks
7:35 AM
Questions & Answers

Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, hematologist-oncologists, advanced practice providers, and other health care providers who treat patients with WM.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

  • Evaluate current recommended treatment options, describe when it is appropriate to initiate treatment for WM patients, and optimize outcomes for patients with WM
  • Identify emerging treatment advances and understand the implications of current real-world treatment outcomes data for patients with WM

Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and RedMedEd. Purdue University College of Pharmacy is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University College of Pharmacy designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Access Statement
RedMedEd complies fully with the legal requirements of the Americans With Disabilities Act. If you are in need of special accommodation, please indicate your need in writing and send to hrafa@redmeded.com or contact Heather Rafa at 610.251.6841.

Jointly provided by

This symposium is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.